Medindia

X

Collexis and SyynX Solutions Present Healthcare Case Study

Wednesday, August 22, 2007 General News J E 4
Advertisement
COLUMBIA, S.C., Aug. 22 Collexis Holdings, Inc.(OTC Bulletin Board: CLXS), a leading developer of knowledge management (KM)and discovery software, announced today a case study describing the successfulintroduction of a knowledge and skills management system from SyynX Solutions,based on Collexis patented Fingerprint technology, will be a featured topic atthe Massachusetts Health Data Consortium. The consortium, co-sponsored byCollexis, is aimed at hospital CIOs and CMOs and will be held at theconsortium offices at 460 Totten Pond Road, Waltham, MA this August 23.

The case study took place within the Asklepios Hospital Group, which isthe largest privately owned healthcare provider in Germany, operating over 90medical facilities in Germany plus several facilities in the United States.The Group's challenge was to increase closer cooperation among practitioners,create more intensive communications and better cross-institutional knowledgetransfer. Asklepios needed a solution that would make relevant knowledge forpatient care quickly available to doctors. The solution needed to be capableof integration into the Future Hospital Program, which involves a partnershipbetween Asklepios, Intel and Microsoft. The answer was creating a centralknowledge and skills management system developed and implemented by SyynXSolutions, the German partner of Collexis Holdings, Inc. The CollexisFingerprint Engine is a primary component of this system utilizing automateddocument analysis, which enables expertise profiling or identification ofexperts within Asklepios who best fit a specific patient case orscientific/medical task.

Bill Kirkland, CEO, Collexis Holdings, Inc. comments, "It is particularlygratifying to work with the prestigious Asklepios Hospital Group as itutilizes knowledge management tools to find, share and integrate informationmore easily and effectively."

Featured speaker, Dr. Christian Herzog, Managing Director, SyynXSolutions, adds, "We welcomed the opportunity to develop a central knowledgeand skills management systems using our SyynX Clinical Solutions powered bythe patented Collexis Fingerprint to solve the unique challenges ofAsklepios."

In addition to Dr. Christian Herzog, featured speakers include Mr. UwePottgen, CIO, Asklepios and Dr. Ron Ribitzky, Senior Healthcare Strategist,Intel. As well as the Asklepios Hospital Group, Collexis products andservices are utilized by Johns Hopkins University, Harvard University's DanaFarber Cancer Institute, the University of California, San Francisco, theUniversity of South Carolina, Merck & Co., Inc., Bristol-Myers Squibb,Lockheed Martin, the World Health Organization, the National Institutes ofHealth and the US Department of Defense.

Collexis Holdings, Inc.

Collexis Holdings, Inc., a global knowledge discovery company since 1999,is headquartered in Columbia, South Carolina (USA) with two subsidiaries;Collexis Inc. in Columbia, South Carolina, USA and Collexis, B.V. inGeldermalsen, The Netherlands. Collexis' patented technology buildsconceptual profiles of text, called Fingerprints, from documents, websites, e-mails and other digitized content to create applications. The results areoften described as "finding needles in many haystacks." Through this novelapproach, Collexis can build unique applications to search, index, andaggregate information as well as prioritize, trend and predict data based onsources in multiple fields, without the limitations of language or dialect.The company's mission is to develop software supporting knowledge retrievaland discovery across multiple industries. For more information visitwww.collexis.com.

This press release contains forward-looking statements. Such statementsare valid only as of today, and we disclaim any obligation to update thisinformation. These statements are subject to known and unknown risks anduncertainties that
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Operon Biotechnologies and DNA2.0 Announce Co-Mark...
S
Breakthrough Kitchen Appliance Removes E.Coli, Lis...